Omicron worries spur 2% slide in European stocks By Reuters

© Reuters. FILE PHOTO: The Gold exchangeGerman share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, December 17, 2021. REUTERS/Staff

By Anisha Sircar

(Reuters) -European stocks fell more than 2% on Monday amid a global sell-off in equities, with investors fretting over the spectre of tighter pandemic curbs hitting the global economy as cases of the Omicron COVID-19 variant surge.

The pan-European STOXX 600 was down 2.2%, falling to its lowest in more than two weeks.

Travel, oil and auto stocks led declines with losses of more than 3%, with all the major subsectors in the red.

"The rate at which the virus is picking up is increasing fears that governments are going to bring in tighter restrictions which could curtail movement and hamper economic activity," said David Madden, market analyst at CMC Markets UK.

The Netherlands imposed a lockdown on Sunday, while the prospect of tighter COVID-19 measures ahead of the Christmas and New Year holidays looms large over several European countries amid the swift spread of Omicron.

Madden added that lower liquidity in the last weeks of December could also be leading to the exacerbated moves.

Last week, the STOXX 600 rallied after the European Central Bank promised continued economic support and the U.S. Federal Reserve flagged a long-awaited end to its pandemic-era stimulus in March, while delivering an upbeat outlook.

Meanwhile, futures tracking the U.S. stocks benchmark S&P 500 skid 1.8% after U.S. Senator Joe Manchin, a moderate Democrat who is key to President Joe Biden's hopes of passing a $1.75 trillion domestic investment bill, said on Sunday he would not support the package.

Goldman Sachs (NYSE:GS) cut U.S. real GDP forecast for the first quarter of 2022 to 2% versus 3% previously, and marginally reduced forecasts for the second and third quarters.

Shares in argenx leaped 8.2% to the top of the benchmark after the Belgian group reached a regulatory milestone for its receptor blocker.

The worst performer, however, was Novo Nordisk (NYSE:NVO), which plunged 10.8% after the Danish drugmaker said it would not be able to meet demand for its new obesity drug due to U.S. supply issues.

BNP Paribas (OTC:BNPQY) slipped 0.6% after the French lender agreed to sell its U.S. unit, Bank of the West, to Canada's BMO Financial Group for around $16.3 billion.

Sweden's BillerudKorsnas dropped 6.9% after saying it would buy U.S.-based coated paper producer Verso (NYSE:VRS) for around $825 million in cash as the pulp and paper manufacturer looks to expand into North America.

Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!